Liz Wager: Why aren’t researchers told about reporting guidelines?

I recently gave a talk about guidelines to a group of postgraduate students at a well known, well resourced, and ancient university. The purpose of my talk was to explain the guidelines governing professional medical writers, as this was a careers day for biomedical researchers, who were considering a move into the world of medical […]

Read More…

Zoe Smith: Changing the story for neglected tropical diseases

While it’s been challenging to make neglected tropical diseases (NTDs) a priority on the global health agenda, until recently, the struggle to raise the conversation beyond niche circles has been even harder. The illnesses are prevalent in places that many would struggle to find on a map, let alone pronounce (echinococcosis and onchocerciasis, for example). Factors […]

Read More…

Jim Murray: A surprising development in the case of InterMune vs the EMA

InterMune has withdrawn part of its legal challenge to stop the European Medicines Agency from disclosing certain documents, which relate to the medicine Esbriet (Pirfenidone). The company is still looking for a prohibition on disclosure, but has withdrawn its application for an interim order, which would prevent disclosure before the full hearing of the case. (InterMune […]

Read More…

Chris Hopson: You get what you pay for—a different approach to the 2015/16 NHS tariff is crucial

If you get what you pay for, then 2015/16 risks being a very difficult year for the NHS, as the system affordability challenge, according to Monitor, jumps from 3.1% to 6.6%. This is driven by increasing demand and costs, a flat NHS budget, changes to NHS pension arrangements, and the *Better Care Fund. NHS providers […]

Read More…